Skip to main content

Prostate Cancer

Volume 448: debated on Monday 3 July 2006

To ask the Secretary of State for Health what assessment her Department has made of the efficacy of the use of Docetaxel in the treatment of prostate cancer. (79414)

The National Institute for Health and Clinical Excellence has conducted an appraisal of Docetaxel for the treatment of hormone refractory prostate cancer and published its guidance to the national health service on 28 June